The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
Open accessAbstract
Anti-programmed cell death protein 1 (PD-1) agents have become the standard of care for platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and are currently being evaluated in various disease settings. However, despite the gain in overall survival seen in some of the clinical trials, the majority of patients display primary resistance and do not benefit from these agents. Taking into consideration the potentially severe immune-related toxicities and their high cost, the search for predictive biomarkers of response is crucial. Besides Programmed death ligand-1 (PD-L1) expression, other biomarkers such as immune infiltration, tumor mutational burden or immune-gene expression profiling have been explored, but none of them has been validated in this disease. Among these, the microbiota has recently garnered tremendous interest since it has proven to influence the efficacy of PD-1 blockade in some tumor types. With the accumulating evidence on the effect of the microbiota in HNSCC tumorigenesis and progression, the study of its potential role as a predictive immune biomarker is warranted. This review examines the available evidence on emerging immune predictive biomarkers of response to anti-PD-1/PD-L1 therapy in HNSCC, introducing the microbiota and its potential use as a predictive immune biomarker in this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
TIGIT predominantly regulates the immune response via regulatory T cells
Kurtulus, S., Sakuishi, K., Ngiow, S.-F., Joller, N., Tan, D. J., Teng, M. W. L., Smyth, M. J., Kuchroo, V. K., & Anderson, A. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81187 · Cited by 551
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“Up to 60% of patients across different tumor types, including HNSCC, display primary resistance to anti-PD-1/PD-L1 agents [11].”
BackgroundPembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · cited 1×
“These tumors have been shown to be particularly sensitive to ICI in prospective clinical trials, leading to the FDA approval of pembrolizumab for patients with dMMR or MSI-H tumors, regardless of histology [112, 113].”
BackgroundNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 1×
“These tumors have been shown to be particularly sensitive to ICI in prospective clinical trials, leading to the FDA approval of pembrolizumab for patients with dMMR or MSI-H tumors, regardless of histology [112, 113].”
BackgroundHuman Papillomavirus and Survival of Patients with Oropharyngeal Cancer
Ang, K. K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D. I., Nguyen-Tân, P. F., Westra, W. H., Chung, C. H., Jordan, R. C., Lu, C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912217 · Cited by 6,566
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 2×
“One of the most relevant is the lack of uniformity in the assays and the variability in the thresholds used to define PD-L1 positivity, which have led to the launch of harmonization projects on PD-L1 assays by the scientific community and regulatory agencies [28, 35, 36].”
BackgroundResultNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101 · cited 8×
“Smoking • Smokers versus nonsmokers • Smoking mutational signatures in tumor samples Negative No data Uncertain No data Retrospective analysis of prospective trials [9].”
BackgroundResultInfluentialGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 2×
“The predictive role of the oral microbiota was also investigated in melanoma patients treated with anti-PD-1/ PD-L1 therapy, again reporting no association with treatment outcome, in contrast to the positive correlation observed with the intestinal microbiota composition [22].”
ResultGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“Two preclinical studies using mouse models of melanoma and lung cancer revealed a correlation between the presence of specific commensal intestinal bacteria (Bifidobacterium) and response to ICI [20, 132].”
BackgroundComprehensive genomic characterization of head and neck squamous cell carcinomas
The Cancer Genome Atlas Network (2015) · Nature · doi:10.1038/nature14129 · Cited by 3,877
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · cited 1×
“Tumors characterized by mutations affecting DNA damage response, such as those with microsatellite instability high (MSI-H) or mismatch repair deficiency (dMMR), have the highest mutational load [77, 111].”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 1×
“Two preclinical studies using mouse models of melanoma and lung cancer revealed a correlation between the presence of specific commensal intestinal bacteria (Bifidobacterium) and response to ICI [20, 132].”
BackgroundPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230 · cited 3×
“An initial retrospective analysis of 27 tumor types and subtypes among patients who received PD-1/PD-L1 inhibitors demonstrated a significant correlation between TMB and response rate to these agents [77].”
BackgroundZou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
Yu, T., Guo, F., Yu, Y., Sun, T., Ma, D., Han, J., Qian, Y., Kryczek, I., Sun, D., Nagarsheth, N., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.008 · Cited by 2,198
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745 · cited 1×
“This hypothesis was initially supported by the results from the HNSCC cohort of the multibasket phase I KEYNOTE-012 trial in which HPVþ tumors had increased ORR to pembrolizumab compared with those that were HPV (25%–32% versus 14%) [6, 7].”
ResultReciprocal interactions of the intestinal microbiota and immune system
Maynard, C. L., Elson, C. O., Hatton, R. D., & Weaver, C. T. (2012) · Nature · doi:10.1038/nature11551 · Cited by 1,598
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Garrett, W. S. (2015) · Science · doi:10.1126/science.aaa4972 · Cited by 1,404
The molecular landscape of head and neck cancer
Leemans, C. R., Snijders, P. J. F., & Brakenhoff, R. H. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.11 · Cited by 1,395
Mechanisms of resistance to immune checkpoint inhibitors
Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D., Vennapusa, B., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,270
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Mlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034
Microbiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883
Chow, L. Q. M., Haddad, R., Gupta, S., Mahipal, A., Mehra, R., Tahara, M., Berger, R., Eder, J. P., Burtness, B., Lee, S.-H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1478 · Cited by 857
Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., et al. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.04.008 · Cited by 804
TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
Chauvin, J.-M., Pagliano, O., Fourcade, J., Sun, Z., Wang, H., Sander, C., Kirkwood, J. M., Chen, T.-H. T., Maurer, M., Korman, A. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80445 · Cited by 784
Lyford-Pike, S., Peng, S., Young, G. D., Taube, J. M., Westra, W. H., Akpeng, B., Bruno, T. C., Richmon, J. D., Wang, H., Bishop, J. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2384 · Cited by 777
The head and neck cancer immune landscape and its immunotherapeutic implications
Mandal, R., Şenbabaoğlu, Y., Desrichard, A., Havel, J. J., Dalin, M. G., Riaz, N., Lee, K.-W., Ganly, I., Hakimi, A. A., Chan, T. A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89829 · Cited by 765
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3973 · Cited by 637
Saâda-Bouzid, E., Defaucheux, C., Karabajakian, A., Coloma, V. P., Servois, V., Paoletti, X., Even, C., Fayette, J., Guigay, J., Loirat, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx178 · Cited by 596
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
Lui, V. W. Y., Hedberg, M. L., Li, H., Vangara, B. S., Pendleton, K., Zeng, Y., Lu, Y., Zhang, Q., Du, Y., Gilbert, B. R., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0103 · Cited by 589
Resistance to PD1/PDL1 checkpoint inhibition
O'Donnell, J. S., Long, G. V., Scolyer, R. A., Teng, M. W. L., & Smyth, M. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.007 · Cited by 572
Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541 · cited 1×
“In this regard, the predictive value of response to ICIs offered by immunophenotyping of circulating T-cell subsets versus TILs has demonstrated relevance in melanoma and NSCLC but it is still unknown in HNSCC [100, 101].”
BackgroundHamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534 · cited 1×
“For instance, CD8þ T-cell infiltration at baseline has been correlated with increased response to anti-PD-1/PD-L1 agents in melanoma [81, 82].”
BackgroundTumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87324 · Cited by 525
The gut microbiota influences anticancer immunosurveillance and general health
Routy, B., Gopalakrishnan, V., Daillère, R., Zitvogel, L., Wargo, J. A., & Kroemer, G. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0006-2 · Cited by 523
Chemotherapy‐driven dysbiosis in the intestinal microbiome
Montassier, E., Gastinne, T., Vangay, P., Al‐Ghalith, G. A., Bruley des Varannes, S., Massart, S., Moreau, P., Potel, G., de La Cochetière, M. F., Batard, E., et al. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13302 · Cited by 515
APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity
Swanton, C., McGranahan, N., Starrett, G. J., & Harris, R. S. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0344 · Cited by 488
Cancer and the gut microbiota: An unexpected link
Zitvogel, L., Galluzzi, L., Viaud, S., Vétizou, M., Daillère, R., Merad, M., & Kroemer, G. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010473 · Cited by 465
Human papillomavirus-related oropharyngeal cancer
Taberna, M., Mena, M., Pavón, M. A., Alemany, L., Gillison, M. L., & Mesía, R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx304 · Cited by 399
Self-citationThommen, D. S., Schreiner, J., Müller, P., Herzig, P., Roller, A., Belousov, A., Umana, P., Pisa, P., Klein, C., Bacac, M., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0097 · Cited by 395
Henderson, S., Chakravarthy, A., Su, X., Boshoff, C., & Fenton, T. R. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.012 · Cited by 345
de Ruiter, E. J., Ooft, M. L., Devriese, L. A., & Willems, S. M. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356148 · Cited by 340
Pushalkar, S., Ji, X., Li, Y., Estilo, C., Yegnanarayana, R., Singh, B., Li, X., & Saxena, D. (2012) · BMC Microbiology · doi:10.1186/1471-2180-12-144 · Cited by 339
Cimino-Mathews, A., Thompson, E., Taube, J. M., Ye, X., Lu, Y., Meeker, A., Xu, H., Sharma, R., Lecksell, K., Cornish, T. C., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2015.09.003 · Cited by 336
Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer
Hayes, R. B., Ahn, J., Fan, X., Peters, B. A., Ma, Y., Yang, L., Agalliu, I., Burk, R. D., Ganly, I., Purdue, M. P., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4777 · Cited by 332
Guerrero-Preston, R., Godoy-Vitorino, F., Jedlicka, A., Rodríguez-Hilario, A., González, H., Bondy, J., Lawson, F., Folawiyo, O., Michailidi, C., Dziedzic, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9710 · Cited by 313
Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer
Donnem, T., Hald, S. M., Paulsen, E.-E., Richardsen, E., Al-Saad, S., Kilvaer, T. K., Brustugun, O. T., Helland, A., Lund-Iversen, M., Poehl, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1905 · Cited by 312
Siu, L. L., Even, C., Mesía, R., Remenar, E., Daste, A., Delord, J.-P., Krauss, J., Saba, N. F., Nabell, L., Ready, N. E., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4628 · Cited by 309
Self-citationHeery, C. R., O'Sullivan-Coyne, G., Madan, R. A., Cordes, L., Rajan, A., Rauckhorst, M., Lamping, E., Oyelakin, I., Marté, J. L., Lepone, L. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30239-5 · Cited by 305
The Role of the Microbiota in Inflammation, Carcinogenesis, and Cancer Therapy
Dzutsev, A., Goldszmid, R. S., Viaud, S., Zitvogel, L., & Trinchieri, G. (2015) · European Journal of Immunology · doi:10.1002/eji.201444972 · Cited by 300
Jie, H.-B., Gildener-Leapman, N., Li, J., Srivastava, R. M., Gibson, S. P., Whiteside, T. L., & Ferris, R. L. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.645 · Cited by 286
Frameshift events predict anti–PD-1/L1 response in head and neck cancer
Hanna, G. J., Lizotte, P., Cavanaugh, M., Kuo, F. C., Shivdasani, P., Frieden, A., Chau, N. G., Schoenfeld, J. D., Lorch, J. H., Uppaluri, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98811 · Cited by 275
Kim, H. R., Ha, S.-J., Hong, M. H., Heo, S. J., Koh, Y. W., Choi, E. C., Kim, E. K., Pyo, K. H., Jung, I., Seo, D., et al. (2016) · Scientific Reports · doi:10.1038/srep36956 · Cited by 256
Wang, S., Jia, M., He, Z., & Liu, X.-S. (2018) · Oncogene · doi:10.1038/s41388-018-0245-9 · Cited by 254
Kansy, B. A., Concha-Benavente, F., Srivastava, R. M., Jie, H.-B., Shayan, G., Lei, Y., Moskovitz, J., Moy, J., Li, J., Brandau, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3167 · Cited by 246
Darb-Esfahani, S., Kunze, C. A., Kulbe, H., Sehouli, J., Wienert, S., Lindner, J., Budczies, J., Bockmayr, M., Dietel, M., Denkert, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6429 · Cited by 244
Bacterial metabolism affects the C. elegans response to cancer chemotherapeutics
García-González, A. P., Ritter, A. D., Shrestha, S., Andersen, E. C., Yilmaz, L. S., & Walhout, A. J. M. (2017) · Cell · doi:10.1016/j.cell.2017.03.046 · Cited by 243
Partlová, S., Bouček, J., Kloudová, K., Lukešová, E., Zábrodský, M., Grega, M., Fučíková, J., Truxová, I., Tachezy, R., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.4161/21624011.2014.965570 · Cited by 241
The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck
Zandberg, D. P., & Strome, S. E. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2014.04.003 · Cited by 239
Overall survival and PD‐L1 expression in metastasized malignant melanoma
Gadiot, J., Hooijkaas, A. I., Kaiser, A. D. M., van Tinteren, H., van Boven, H., & Blank, C. (2011) · Cancer · doi:10.1002/cncr.25747 · Cited by 221
Larkins, E., Blumenthal, G. M., Yuan, W., He, K., Sridhara, R., Subramaniam, S., Zhao, H., Liu, C., Yu, J., Goldberg, K. B., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0496 · Cited by 218
Molling, J. W., Langius, J. A. E., Langendijk, J. A., Leemans, C. R., Bontkes, H. J., van der Vliet, H. J. J., von Blomberg, B. M. E., Scheper, R. J., & van den Eertwegh, A. J. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5787 · Cited by 205
Exploring the link between microorganisms and oral cancer: A systematic review of the literature
Hooper, S. J., Wilson, M. J., & Crean, S. J. (2009) · Head & Neck · doi:10.1002/hed.21140 · Cited by 202
Meurman, J. H. (2010) · Journal of Oral Microbiology · doi:10.3402/jom.v2i0.5195 · Cited by 190
Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas
Desrichard, A., Kuo, F., Chowell, D., Lee, K.-W., Riaz, N., Wong, R. J., Chan, T. A., & Morris, L. G. T. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy060 · Cited by 176
Davis, R. J., Van Waes, C., & Allen, C. T. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.05.002 · Cited by 163
Glaser, A. P., Fantini, D., Wang, Y., Yu, Y., Rimar, K. J., Podojil, J. R., Miller, S. D., & Meeks, J. J. (2017) · Oncotarget · doi:10.18632/oncotarget.23344 · Cited by 159
Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015
Galon, J., Fox, B. A., Bifulco, C. B., Masucci, G. V., Rau, T. T., Botti, G., Marincola, F. M., Ciliberto, G., Pagès, F., Ascierto, P. A., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1029-z · Cited by 156
The breakthrough of the microbiota
Kroemer, G., & Zitvogel, L. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2018.4 · Cited by 147
PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development
Hansen, A. R., & Siu, L. L. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4685 · Cited by 144
Self-citationLechner, A., Schlößer, H., Rothschild, S. I., Thelen, M., Reuter, S., Zentis, P., Shimabukuro‐Vornhagen, A., Theurich, S., Wennhold, K., Garcia-Marquez, M. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17901 · Cited by 140
Burtness, B. A., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A. K., Rotllan, N. B., Neupane, P., Bratland, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.045 · Cited by 140
Solomon, B., Young, R. J., Bressel, M., Urban, D., Hendry, S. A., Thai, A. A., Angel, C. M., Haddad, A., Kowanetz, M., Fua, T. F., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0299 · Cited by 137
Skinner, H. D., Giri, U. P., Yang, L. P., Kumar, M., Liu, Y., Story, M. D., Pickering, C. R., Byers, L. A., Williams, M. D., Wang, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2586 · Cited by 131
The interplay between HPV and host immunity in head and neck squamous cell carcinoma
Andersen, A. S. M., Sølling, A. S., Ovesen, T., & Rusan, M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28411 · Cited by 130
Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma.
Russell, S., Angell, T., Lechner, M. G., Liebertz, D., Correa, A., Sinha, U. K., Kokot, N., & Epstein, A. (2013) · PubMed · Cited by 124
Promising systemic immunotherapies in head and neck squamous cell carcinoma
Gildener‐Leapman, N., Ferris, R. L., & Bauman, J. E. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.09.009 · Cited by 122
The oral cavity microbiota: between health, oral disease, and cancers of the aerodigestive tract
Bars, P. L., Matamoros, S., Montassier, E., Vacon, F. L., Potel, G., Soueidan, A., Jordana, F., & de la Cochetière, M.-F. (2017) · Canadian Journal of Microbiology · doi:10.1139/cjm-2016-0603 · Cited by 119
Mattox, A. K., Lee, J., Westra, W. H., Pierce, R. H., Ghossein, R. A., Faquin, W. C., Diefenbach, T. J., Morris, L. G. T., Lin, D. T., Wirth, L. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3453 · Cited by 111
Guerrero-Preston, R. E., White, J. R., Godoy‐Vitorino, F., Rodríguez-Hilario, A., Navarro, K., González, H., Michailidi, C., Jedlicka, A., Canapp, S., Bondy, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20677 · Cited by 109
Karpathiou, G., Casteillo, F., Giroult, J.-B., Forest, F., Fournel, P., Monaya, A., Froudarakis, Μ. E., Dumollard, J. M., Prades, J. M., & Péoc’h, M. (2016) · Oncotarget · doi:10.18632/oncotarget.14242 · Cited by 104
Gene-expression profiling to predict responsiveness to immunotherapy
Jamieson, N. B., & Maker, A. V. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.63 · Cited by 92
Zhou, J., Gong, Z., Jia, Q., Wu, Y., Yang, Z., & Zhu, B. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.053 · Cited by 92
Gandara, D. R., Kowanetz, M., Mok, T. S. K., Rittmeyer, A., Fehrenbacher, L., Fabrizio, D. A., Otto, G. A., Malboeuf, C. M., Lieber, D. S., Paul, S. M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx380 · Cited by 87
Oguejiofor, K., Galletta, H., Dovedi, S. J., Roberts, D. L., Stern, P. L., & West, C. (2017) · Oncotarget · doi:10.18632/oncotarget.14796 · Cited by 82
Segal, N. H., Ou, S. I., Balmanoukian, A. S., Fury, M. G., Massarelli, E., Brahmer, J. R., Weiss, J., Schöffski, P., Antonia, S. J., Massard, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3011 · Cited by 80
Harnessing the Microbiome to Enhance Cancer Immunotherapy
Nelson, M. H., Diven, M. A., Huff, L. W., & Paulos, C. M. (2015) · Journal of Immunology Research · doi:10.1155/2015/368736 · Cited by 78
Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).
Haddad, R. I., Seiwert, T. Y., Chow, L. Q. M., Gupta, S., Weiss, J., Gluck, I., Eder, J. P., Burtness, B. A., Tahara, M., Keam, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.6009 · Cited by 58
Galsky, M. D., Saci, A., Szabó, P. M., Azrilevich, A., Horak, C. E., Lambert, A., Siefker-Radtke, A. O., Necchi, A., & Sharma, P. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx371.003 · Cited by 56
Zhuo, M., Chen, H., Zhang, T., Yang, X., Zhong, J., Wang, Y., An, T., Wu, M., Wang, Z., Huang, J., et al. (2018) · Cancer Biomarkers · doi:10.3233/cbm-171089 · Cited by 44
Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)
Seiwert, T. Y., Haddad, R. I., Bauml, J. M., Weiss, J., Pfister, D. G., Gupta, S., Mehra, R., Gluck, I., Kang, H., Worden, F. P., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-lb-339 · Cited by 38
Cohen, E. E. W., Machiels, J., Harrington, K. J., Burtness, B. A., Shin, S. W., Gause, C. K., Swift, A. M., Brown, H. M., Perrone, A. M., Cheng, J. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.tps6084 · Cited by 34
Zandberg, D. P., Algazi, A. P., Jimeno, A., Good, J., Fayette, J., Bouganim, N., Ready, N., Clement, P., Goswmi, T., Jarkowski, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx374 · Cited by 31
Ferris, R. L., Blumenschein, G. R., Harrington, K. J., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L. F., Vokes, E. E., Gillison, M. L., Even, C., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct022 · Cited by 26
Huang, S. H., O’Sullivan, B., & Waldron, J. N. (2017) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2017.08.007 · Cited by 26
Precision Medicine in Head and Neck Cancer: Myth or Reality?
Malone, E. R., & Siu, L. L. (2018) · Clinical Medicine Insights Oncology · doi:10.1177/1179554918779581 · Cited by 26
Self-citationBahleda, R., Braiteh, F. S., Balmanoukian, A. S., Braña, I., Hodi, F. S., Garbo, L. E., Liu, B., Molinero, L. L., O'Hear, C. E., Shen, X., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx374.001a · Cited by 25
Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma
Okada, S., Itoh, K., Ishihara, S., Shimada, J., Kato, D., Tsunezuka, H., Miyata, N., Hirano, S., Teramukai, S., & Inoue, M. (2018) · Surgical Oncology · doi:10.1016/j.suronc.2018.04.007 · Cited by 21
Anti-cancer therapies affected by gut microbiota
Greenhill, C. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.238 · Cited by 19
Ishii, H., Azuma, K., Kawahara, A., Matsuo, N., Tokito, T., Kinoshita, T., Yamada, K., Sasada, T., Akiba, J., & Hoshino, T. (2017) · Oncotarget · doi:10.18632/oncotarget.18651 · Cited by 18
Rittmeyer, A., Gandara, D. R., Kowanetz, M., Mok, T. S. K., Fehrenbacher, L., Fabrizio, D. A., Otto, G. A., Malboeuf, C. M., Lieber, D. S., Paul, S., et al. (2018) · Pneumologie · doi:10.1055/s-0037-1619250 · Cited by 13
Cited by
Pattern recognition receptors in health and diseases
Li, D., & Wu, M. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00687-0 · Cited by 1,787
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 507
Targeting the gut and tumor microbiota in cancer
Park, E. M., Chelvanambi, M., Bhutiani, N., Kroemer, G., Zitvogel, L., & Wargo, J. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01779-2 · Cited by 496
An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma
Chen, Y., Li, Z.-Y., Zhou, G.-Q., & Sun, Y. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2166 · Cited by 268
Metadata
- Authors
- Oliva, M., Spreafico, A., Taberna, M., Alemany, L., Coburn, B., Mesia, R., & Siu, L. L.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 30
- Issue
- 1
- Pages
- 57-67
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2901903079
- Cited by
- 260
- References
- 124
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.